I am hitting you with two episodes today folks, our Sunday night review of ES & SPY will be out later this evening.
But this episode is different to anything I have done before. As you may know, I am slowly going to be getting more into small caps over the course of this year. There are two stocks that I have been speaking about for some time now, and I want to share my thoughts on them. This is not an encouragement to buy - instead just watch and see how it pans out and as I begin to do more of these types of posts, hopefully you will see whether it is something you want to dip your toes into or not.
So let’s get stuck in…
Small Caps is a strange world, full of trash companies that get thrown around by pump and dump furus like doobie that hits too hard. Sometimes the market hands you a doobie that is just too good to pass on. Today, let’s take cheeky puff on why PRPH and CLBR still feel like “why not?” setups— no hard sell, just the latest dirt I’ve dug up. If you follow me on Twitter and Discord, you will know we have already made money on these two, with CLBR options going 400% and PRPH stock going %100. But the fun and fireworks aren’t quite over, in fact, some would say they are only just getting started, so let’s find out why…
PRPH: The Phoenix of Biomedical Stocks?
1. New Science Board & A Cancer-Detecting Test
On June 6, ProPhase unveiled a Clinical Science Advisory Board to help commercialize BE-Smart™—their esophageal disease platform—then on June 17 they announced a successful study showing BE-Smart™ can actually sniff out esophageal cancer early ir.prophaselabs.com. With success rates of over 90% efficiency for a cancer that has a market spend in the billions? That’s real validation, not just another PowerPoint.
The board themselves are a group of super elites in the biomed world, with the new CEO’s last business selling for 6000% return to shareholders. A similar story is true of their new COO and the executive branch have all taking a pay deduction to commit to increasing shareholder revenue in the short term and showing that they are seriously not going to consider a reverse split to improve their stock price. Impressive.
2. Balance Sheet Gymnastics
Let’s get our hands dirty with the numbers: Q1 2025 wasn’t pretty in revenue, but ProPhase went on a cost-cutting tear: they used $4 million in operations plus $1.5 million to retire notes, offset by $3.5 million raised from equity and debt—and even squeezed out $800 K from the sale of their PharmaLoz unit. The net result? Cash slumped to $88 K (from $678 K), but working capital flipped to a $718 K surplus, and stockholders’ equity nearly doubled to $15.1 million from $7.4 million ir.prophaselabs.comir.prophaselabs.com. Behind the scenes they’ve jettisoned non-core units, shut down a genomics lab to save $6 million/year, and gone from 96 heads down to about 25 full-timers globenewswire.com.
Lastly, keep in mind that in February we were made aware that the company is due to get around $50m in covid recievables in the 2nd half of this year and you can begin to see why this stock is refusing to die and why we constant have a flutter of buying whenever they are dropping or due to drop news!
3. Technicals: Charts Whispering “You Up?”
I have been screaming buy on PRPH whenever it is in the 20s. Shares have crept back up to about $0.367 (June 27 close) after a 7% pop that day stocktitan.netintellectia.ai. The short-term 20-day SMA just crossed above the 60-day, a textbook mid-term bullish signal, while resistance clusters at $0.48–$0.54 and support at $0.31–$0.23. Volume ticked higher on the latest rally—always a nice tailwind.
Depending on what your risk appetite is on this one, you could flip at 50%, flip at 100% or wait for the $1 break and see if the fun really begins past this point! Filings show us that executive compensation won’t be paid until the stock is valued at $6. Interesting! If you wanted to turn into an investor rather than a scalper on this one, I could understand why and I may yet join you.
4. Risk Management: Because Running Without a Parachute Is Silly
Remember that Nasdaq’s got them on the clock: Like with any stock valued below $1, PRPH needs to hit $1.00 for 10 straight business days by December 22, 2025 or risk delisting stocktitan.net. That’s a weight around the ankle, so I’m only nibbling with one eye on the clock.
5. Macro Tailwind: Personalized Medicine Still Gets Its Day
Diagnostics and genomics remain secular darlings: even though Q1 revenue missed at $1.43 million vs. $2.45 million consensus, EPS beat at –$0.12 vs. –$0.18 estimate marketbeat.com. In my book, a penny stock that can still surprise to the upside on the bottom line is worth a speculative flutter.
CLBR: When Guns, Boards, and Bell-Ringing Align
1. Why It’s Still Worth Around $20
Even though I have been pounding the table on this one every time is goes sub $13, there’s more to come. Colombier II’s Extraordinary General Meeting is locked in for July 15, 2025—vote day for the GrabAGun merger—and their S-4 cleared the SEC on June 20, paving the way for that vote. Once approved, the combined entity will relist on the NYSE under “PEW” and “PEWW,” and shareholders will convert into equity in a $150 million deal ( $100 million stock + $50 million cash) colombierspac.comainvest.com.
2. Board, Buzz, and “Bell-Ringing”
In late May, Donald Trump Jr. co-hosted an NYC investor shindig for what the buzz calls the “Amazon of gun sales,” and he’s slated to join the board post-deal nypost.com. Meanwhile, GrabAGun filed its third S-4 amendment on June 16, giving fresh disclosures on their “Compatio” customization platform—think build-your-own AR-15 with a few taps businesswire.com.
3. Technicals: Now With Extra Smoke Signals
CLBR closed around $14.66 on June 27, up about 7.8% that day on a volume surge stockinvest.usintellectia.ai. Intellectia’s model flags a mid-term bullish bias (SMA_20 > SMA_60), with resistance up near $17.66 and $19.31, and support floors around $12.33 and $10.69.
4. Catalyst Calendar: Timely Tailwinds
July 15, 2025: Shareholder vote—if it sails through, we could see renewed retail interest from folks who missed the SPAC run.
Summer Hunting Season: Ammo and accessory seasonality kicks in now; GrabAGun’s mobile-first platform could snag gear-hungry consumers heading to ranges and camps.
Post-Close Upsells: Their Compatio customization tool and planned hunting/apparel bundles add optionality for higher-margin sales down the line businesswire.com.
5. Risks: Because This Is Wall Street
Any hiccup in the SEC’s regulatory review or a “no” vote on July 15 could toss CLBR back toward $10–$11. Plus, firearms retail still courts payment-processor drama and regional legal headwinds—one card processor freeze can zap momentum fast ainvest.com.
So let’s summarise:
How I Tap In
Sizing: PRPH is pure pocket change—maybe 1 % of my book max, with a stop under $0.24.
Entry: I Look to pick up PRPH on dips to the 10-day MA (~$0.355). If it closes below $0.245, wave the white flag until it comes back with volume.
Target: A break above $0.50 could spur a run toward $0.85. But the fun begins above $1 for me.
CLBR Entry: If you missed the initial run, consider nibbling around $12.50–$13.75.
Stop-Loss: A daily close under $12.25 for me is a no-go. If this happens I wait.
Target: Post-close, I’d eye $17–$18—if it sneaks to $20 pre-vote, congratulations; that’s your excuse to lock in gains and let some runners ride.
Parting Words
This is not an invitation to buy, there is no flashing neon sign. Instead, I’m simply saying: PRPH and CLBR each have fresh catalysts, clearer paths out of their funks, and technical setups that make me raise an eyebrow. If you’re the kind who likes to swing at tickers that could surprise, these might tickle your fancy.
Let’s see what the small cap gods bestow upon me.
Much Love,
PW